European Journal of Cancer
Volume 41, Issue 11 , Pages 1547-1550 , July 2005

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer

  • S. Baka

      Affiliations

    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 161 446 3126; fax: +44 161 446 3299.
    • ,
  • M. Ranson

      Affiliations

    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    • ,
  • P. Lorigan

      Affiliations

    • Department of Medical Oncology, Weston Park Hospital, Sheffield, UK
    • ,
  • S. Danson

      Affiliations

    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    • ,
  • K. Linton

      Affiliations

    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    • ,
  • I. Hoogendam

      Affiliations

    • NDDO Representative, UK
    • ,
  • K. Mettinger

      Affiliations

    • Supergen Representative, UK
    • ,
  • N. Thatcher

      Affiliations

    • Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK

Received 10 November 2004 ,Revised 23 February 2005 ,Accepted 1 March 2005.

References 

  1. Joss R, Cavali F, Goldhirsch A. New agents in non small-cell lung cancer. Cancer Treat Rev. 1979;11:205–236
  2. Cohen M, Perevodchikova N, Muggia F. Single agent chemotherapy of lung cancer. In: Lung cancer: Progress in therapeutic research. New York: Raven Press; 1979;
  3. Hans H, Roeth M. Lung cancer. In:  Pinedo H,  Longo D,  Chabner B editor. Cancer chemotherapy and biological response modifiers, Annual 12. Elsevier Science Publishers B.V.; 1991;p. 449–459
  4. Choy H, Kim S, Pyo H. Topoisomerase I inhibitors in the combined modality therapy of lung cancer. Clin Lung Cancer. 2001;2(Suppl. 2):S34–S40
  5. White S, Cheeseman S, Thatcher N. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res. 2000;6:868–873
  6. Braybrooke J, Ranson M, Manegold C. Phase II study of mesylate (DX-8951F) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 2003;41:215–219
  7. Wall M, Wani M, Cook C, et al. Plant antitumor agents. I. The isolation and structure of camptothecin a novel alkaloidal leukaemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc. 1996;88:3888–3890
  8. Wani M, Nickolas A, Wall M. Plant antitumor agents 23 synthesis and antileukemic activity of camptothecin analogues. J Med Chem. 1986;29:2358–2363
  9. Hinz , Harris H, Natelson N, et al. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20 (S0-camptothecin to 9-amino-20 (S) in camptothecin humans, dogs and mice. Cancer Res. 1994;54:3096–3100
  10. Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res. 1995;1:1235–1244
  11. Verschraegen C, Natelson E, Giovanella B, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drug. 1998;9:36–44
  12. Schöffski P, Herr A, Vermorken J, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pre-treated patients with metastatic colorectal cancer – significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer. 2002;38:807–813
  13. Konstadoulakis M, Antonakis P, Tsibloulis P, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2001;48:417–420
  14. Raymond E, Campone M, Stupp R, et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer. 2002;38:1348–1350
  15. Patel S, Beach J, Papadopoulos N, et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer. 2005;97:2848–2852
  16. Ellerhorst A, Bedikian A, Smith T, et al. Phase II trial of 9-nitrocamptothecin (RFS2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drug. 2002;13:169–172
  17. Verschraegen F, Gupta E, Loyer E, et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drug. 1999;10375–10383
  18. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821–1826
  19. EVokes E, Rosenberg R, Jahanzeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J Clin Oncol. 1995;13:637–644
  20. Perez-Soler R, Fossella F, Glisson B, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996;14:503–513
  21. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91, 66–72.
  22. White S, Cheeseman S, Thatcher N, et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res. 2000;6:868–873

PII: S0959-8049(05)00217-0

doi: 10.1016/j.ejca.2005.03.009

European Journal of Cancer
Volume 41, Issue 11 , Pages 1547-1550 , July 2005

Article Tools